Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Sign in Join

February 19 – 25, 2024

Ibogaine Advocates Seek Ohio Opioid Settlement Funds Following Failure in Kentucky

Psychedelic Alpha ↗

The loose coalition of ibogaine funding advocates—led by former Kentucky Opioid Abatement Advisory Commission Chairman Bryan Hubbard—has landed on a new state to house their project: Ohio.

In this article, we explore the magnitude of opioid settlement funds available in Ohio; the funding mechanisms we expect ibogaine advocates to tap in support of their renewed initiative; why advocates believe Ohio makes sense as a potential champion of this work; and, the challenges ahead for such an ambitious project.

February 12 – 18, 2024

Pα+: Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA (Part 1)

Psychedelic Alpha ↗

Two weeks ago, the Reagan-Udall Foundation for the FDA hosted a two-day meeting, Advancing Psychedelic Clinical Study Design. It offered great insight into how academics, industry representatives, and—crucially—the FDA are viewing psychedelic drug development programs.

In this piece, Josh shares some key themes, analysis and take aways.

The Day 2 Dispatch is now available, too. It covers Set and Setting, FDA’s regulatory authority, and real-world use of psychedelics.

Natural Medicine Advisory Bulletin #8: January 2024

Psychedelic Alpha ↗

As Colorado’s Natural Medicine Advisory Board (NMAB) officially adopts an initial set of 123 recommendations, with many having dozens of sub-parts, Vicente LLP review the January 2024 meetings of the NMAB and its subcommittees.

February 1-7, 2024

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.